Skip to main content

Vascular Disease Management News

Large-Bore Closure
10/27/2026
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system...
10/27/2026
Cath Lab Digest
FDA Approvals
10/20/2026
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra,...
10/20/2026
Cath Lab Digest
Vertex PE System (Jupiter Endovascular)
Pulmonary Embolism
10/19/2026
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the...
10/19/2026
Cath Lab Digest
Deep Learning
10/09/2026
Laura Simson, MA
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining...
10/09/2026
Vascular Disease Management
AngioDynamics
10/08/2026
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS...
10/08/2026
Vascular Disease Management
Bioresorbable Scaffolds
10/08/2026
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical,...
10/08/2026
Cath Lab Digest
Lower-Extremity & Stroke Intervention
10/07/2026
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26...
10/07/2026
Cath Lab Digest
Peripheral Intervention
10/07/2026
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies...
10/07/2026
Cath Lab Digest